Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-06-07
2011-06-07
Jarrell, Noble (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S081000
Reexamination Certificate
active
07956064
ABSTRACT:
The invention relates in part to fused tricyclic compounds having certain biological activities that include, but are not limited to, inhibiting cell proliferation, modulating protein kinase activity and modulating polymerase activity. The fused tricyclic compounds of the invention can modulate casein kinase (CK) activity and/or poly(ADP-ribose)polymerase (PARP) activity. The invention also relates in part to methods for using such fused tricyclic compounds.
REFERENCES:
patent: 5624677 (1997-04-01), El-Rashidy et al.
patent: 2006/0029950 (2006-02-01), Whitten et al.
patent: 2006/0074089 (2006-04-01), Whitten et al.
patent: 2006/0264634 (2006-11-01), Whitten et al.
patent: 2009/0239859 (2009-09-01), Chua et al.
patent: 0 552 745 (1993-07-01), None
patent: 5-197241 (1993-08-01), None
patent: 10-282804 (1998-10-01), None
patent: 2002-14550 (2002-01-01), None
patent: 2002-132065 (2002-05-01), None
patent: 2002-156808 (2002-05-01), None
patent: WO 2008/016707 (2008-02-01), None
Hansen et al. Tetrahedron, 2005, 61, 9955-60.
Wermuth. The Practice of Medicinal Chemistry, 1996, pp. 203-237.
Calabrese et al., Clin. Cancer Res. (2003) 9:2711-2718.
Calabrese et al., J. Nat'l Cancer Inst. (2004) 96(1):56-67.
Curtin, Expert Reviews in Molecular Medicine (2005) 7(4).
Jagtap, Nature Rev.: Drug Discovery (2005) 4:421-440.
Li et al., Pain (2005) 115(1-2)182-190.
Paola et al., Eur. J. Pharmacology (2005) 527(1-3):163-171.
Parhar et al., Int. J. Colorectal Dis. (2006) 22(6):601-609.
Ruzzene et al., Biochem J. (2002) 364(Pt. 1):41-47.
U.S. Appl. No. 60/803,864, filed Jun. 3, 2006 (Lim et al.).
U.S. Appl. No. 60/811,990, filed Jun. 8, 2006 (Pierre et al.).
U.S. Appl. No. 60/811,992, filed Jun. 8, 2006 (Nagasawa et al.).
U.S. Appl. No. 60/904,694, filed Mar. 1, 2007 (Nagasawa et al.).
Veuger et al., Cancer Res. (2003) 63:6008-6015.
Ashford et al., Arzneimittel-Forschung (1971) 21(7):937-939.
International Search Report and Written Opinion for PCT/US07/77464, mailed Aug. 5, 2008, 10 pages.
Chua Peter C.
Whitten Jeffrey P.
Cooley LLP
Cylene Pharmaceuticals, Inc.
Jarrell Noble
LandOfFree
Fused tricyclic compounds as serine-threonine protein kinase... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fused tricyclic compounds as serine-threonine protein kinase..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fused tricyclic compounds as serine-threonine protein kinase... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2741435